Methods: Between June 2005 and December 2012, 838 consecutive patients (593 males, 245 females; mean age 63 years; range, 10 to 99 years) who underwent major vascular surgery in our clinic were included. The NLR and PLR were determined by dividing the absolute neutrophil and platelet count by the absolute lymphocyte count.
Results: The mean mortality risk was 2.85 (range 1.67- 4.87) in patients with a NLR of ≥5 and 3.76 (range 2.31- 6.12) in patients with a PLR of ≥200. The proportion of diabetic patients was significantly higher for patients with NLR ≥ 5 ( 63.7%; p = 0 .000) a nd P LR ≥ 200 ( %53.8; p = 0.003).
Conclusion: Our study results showed that increased levels of NLR and PLR were directly correlated with mortality and inversely correlated with survival in the postoperative period and that diabetic patients were under a higher risk.
Statistical analysis
Normally distributed continuous data was presented
using mean values (including ± standard deviation).
Survival rates were calculated utilizing the Kaplan-
Meier method, and comparisons were made using
the log-rank test. Risk estimations were performed
using the Cox regression model. In addition, Breslow’s
generalized Wilcoxon test was employed to determine
the clinical characteristics of the patients, and a
chi-square test was then used to compare them with
regard to the duration of the postoperative hospital
stays of the patients and the differing quartiles of the
NLR and PLR (categorical variables). All statistical
analyses were completed using the SPSS version 16.0
for Windows (SPSS Inc., Chicago, IL, USA) software
program.
There were 108 patient deaths within 30 days of the surgery. We found a significantly higher mean mortality risk of 2.85 (range 1.67-4.87) for the patients with a NLR of ≥5 and this risk was mean 3.76 (range, 2.31-6.12) for those with a PLR ≥200. Furthermore, the proportion of diabetic patients was significantly higher for the patients with an NLR of ≥5 (63.7%; p=0.000) and a PLR of ≥200 (53.8%; p=0.003).
The mean survival time for the patients with an NLR of ≥5 (13.5%) was 14.1 months [95% confidence interval (CI): 11.6-16.5) while it was 16.9 months for those with an NLR of <5 (0.8%) (95% CI: 14.9-18.9) (p=0.001) (Figure 1).
Additionally, the mean survival time for the patients with a PLR of ≥200 was 12.9 months (16.7%) (95% CI: 9.9-15.8) and 16.7 months for those with a PLR of <200 (2.1%) (95% CI: 14.9-18.5) (p= 0.002) (Figure 2).
The NLR has been shown to significantly reflect the likely outcomes of percutaneous coronary intervention (PCI) and CABG.[19,21] In a recent study, Chung et al.[35] examined 252 patients who u nderwent thoracic endovascular aneurysm repair (TEVAR) over a period of 11 years in order to identify the risk factors for late mortality and found that preoperative leukocytosis was an independent factor for late mortality, regardless of the clinical presentation. They also showed that preoperative leukocytosis may assist in risk stratification. Neutrophilia springs from the demargination of neutrophils, delayed apoptosis, and the stimulation of stem cells by growth factors [interleukin 6 and granulocyte colony stimulating factor (GCSF)]. Neutrophils promote plaque rupture as a result of the release of proteolytic enzymes, arachidonic acid derivatives, and superoxide radicals. Therefore, neutrophilia reflects the exaggerated inflammatory condition observed in atherosclerotic patients and is also associated with the cells involved in atherosclerotic plaque instability. Ischemic conditions lead to increased vasculogenesis, and this subsequently implies a chronic adaptation process with neutrophilia. In a study conducted by Haumer et al.,[36] they argued that altered endothelial cells promote the activation of neutrophils, which accelerates the build up of either microvascular or macrovascular occlusive plugs. Previous studies have also shown a relationship between the high values of peripheral thrombocytes and cardiovascular diseases.[9,23,37] In spite of this, Mueller et al.[37] were not able to prove an association between platelet counts and mortality in patients with acute coronary syndrome (ACS). In our study, we found an inverse correlation between high PLRs and survival times. Higher platelet counts may indicate an underlying inflammation because there are several inflammatory mediators which stimulate megakaryocytic proliferation and produce relative thrombocytosis. Furthermore, other studies have shown that patients with coronary artery diseases (CADs) have high levels of platelet monocyte aggregates in their bloodstream, which is correlated with plaque stability.[38]
Diabetic patients run a higher risk of having diffuse disease microvascular dysfunction. Lee et al.[39] determined that a high NLR was an independent predictive factor for major adverse cardiac events in post-MI diabetic patients and that the NLR was also an important predictor of macrovascular disease in diabetic patients in general. We also found significantly higher NLRs and PLRs in diabetic patients compared with those without this disease. It is well known that several metabolic and immunological changes occur in diabetic patients, which may be due to the different roles that neutrophils and lymphocytes have in the inflammatory response in diabetic patients. Several mechanisms, including increased levels of plasma, cortisol, leptin, and insulin, contribute to neutrophilia in diabetic patients. Other factors which may also play a part are advanced glycation end products, oxygen free radicals, and other cytokines, all of which possibly aid in the priming of neutrophils. In addition, the activated neutrophils secrete numerous inflammatory mediators which contribute to the increased levels of oxidative stress (OS), inflammation, necrosis with the resultant worsening prothrombotic states, endothelial dysfunction, plaque rupture, and infarct size.[40]
Declaration of conflicting interests
The authors declared no conflicts of interest with
respect to the authorship and/or publication of this
article.
Funding
The authors received no financial support for the
research and/or authorship of this article.
1) Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris
KA, Fowkes FG; TASC II Working Group. Inter-Society
Consensus for the Management of Peripheral Arterial
Disease (TASC II). J Vasc Surg 2007;45 Suppl S:S5-67.
2) Hansson GK. Inflammation, atherosclerosis, and coronary
artery disease. N Engl J Med 2005;352:1685-95.
3) Danesh J, Collins R, Appleby P, Peto R. Association of
fibrinogen, C-reactive protein, albumin, or leukocyte count
with coronary heart disease: meta-analyses of prospective
studies. JAMA 1998;279:1477-82.
4) Pearson TA, Mensah GA, Alexander RW, Anderson JL,
Cannon RO 3rd, Criqui M, et al. Markers of inflammation
and cardiovascular disease: application to clinical
and public health practice: A statement for healthcare
professionals from the Centers for Disease Control
and Prevention and the American Heart Association.
Circulation 2003;107:499-511.
5) Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG.
Leukocyte count and risk of major coronary heart disease
events. Am J Epidemiol 1992;136:59-70.
6) Kannel WB, Anderson K, Wilson PW. White blood cell count
and cardiovascular disease. Insights from the Framingham
Study. JAMA 1992;267:1253-6.
7) Hajj-Ali R, Zareba W, Ezzeddine R, Moss AJ. Relation of
the leukocyte count to recurrent cardiac events in stable
patients after acute myocardial infarction. Am J Cardiol
2001;88:1221-4.
8) Schlant RC, Forman S, Stamler J, Canner PL. The natural
history of coronary heart disease: prognostic factors after
recovery from myocardial infarction in 2789 men. The
5-year findings of the coronary drug project. Circulation
1982;66:401-14.
9) Sabatine MS, Morrow DA, Cannon CP, Murphy SA,
Demopoulos LA, DiBattiste PM, et al. Relationship
between baseline white blood cell count and degree of coronary artery disease and mortality in patients with
acute coronary syndromes: a TACTICS-TIMI 18 (Treat
Angina with Aggrastat and determine Cost of Therapy
with an Invasive or Conservative Strategy- Thrombolysis in
Myocardial Infarction 18 trial)substudy. J Am Coll Cardiol
2002;40:1761-8.
10) Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes
DJ, Kleiman NS, et al. Impact of preprocedural white
blood cell count on long term mortality after percutaneous
coronary intervention: insights from the EPIC, EPILOG, and
EPISTENT trials. Heart 2003;89:1200-4.
11) Coller BS. Leukocytosis and ischemic vascular disease
morbidity and mortality: is it time to intervene? Arterioscler
Thromb Vasc Biol 2005;25:658-70.
12) Folsom AR, Wu KK, Rosamond WD, Sharrett AR,
Chambless LE. Prospective study of hemostatic factors and
incidence of coronary heart disease: the Atherosclerosis Risk
in Communities (ARIC) Study. Circulation 1997;96:1102-8.
13) Kawaguchi H, Mori T, Kawano T, Kono S, Sasaki J, Arakawa
K. Band neutrophil count and the presence and severity of
coronary atherosclerosis. Am Heart J 1996;132:9-12.
14) Grau AJ, Boddy AW, Dukovic DA, Buggle F, Lichy C,
Brandt T, et al. Leukocyte count as an independent predictor
of recurrent ischemic events. Stroke 2004;35:1147-52.
15) Sweetnam PM, Thomas HF, Yarnell JW, Baker IA, Elwood
PC. Total and differential leukocyte counts as predictors
of ischemic heart disease: the Caerphilly and Speedwell
studies. Am J Epidemiol 1997;145:416-21.
16) Ommen SR, Hodge DO, Rodeheffer RJ, McGregor CG,
Thomson SP, Gibbons RJ. Predictive power of the relative
lymphocyte concentration in patients with advanced heart
failure. Circulation 1998;97:19-22.
17) Ommen SR, Gibbons RJ, Hodge DO, Thomson SP. Usefulness
of the lymphocyte concentration as a prognostic marker in
coronary artery disease. Am J Cardiol 1997;79:812-4.
18) Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen
KR, et al. Which white blood cell subtypes predict increased
cardiovascular risk? J Am Coll Cardiol 2005;45:1638-43.
19) Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt
DL. Usefulness of an elevated neutrophil to lymphocyte
ratio in predicting long-term mortality after percutaneous
coronary intervention. Am J Cardiol 2006;97:993-6.
20) Upadhya B, Applegate RJ, Sane DC, Deliargyris EN, Kutcher
MA, Gandhi SK, et al. Preprocedural white blood cell count
and major adverse cardiac events late after percutaneous
coronary intervention in saphenous vein grafts. Am J Cardiol
2005;96:515-8.
21) Gibson PH, Croal BL, Cuthbertson BH, Small GR, Ifezulike
AI, Gibson G, et al. Preoperative neutrophil-lymphocyte
ratio and outcome from coronary artery bypass grafting. Am
Heart J 2007;154:995-1002.
22) Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF.
Blood platelet count and function are related to total and
cardiovascular death in apparently healthy men. Circulation
1991;84:613-7.
23) Iijima R, Ndrepepa G, Mehilli J, Bruskina O, Schulz S,
Schömig A, et al. Relationship between platelet count
and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thromb
Haemost 2007;98:852-7.
24) Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE,
Sadeghi M, et al. Impact of baseline platelet count in patients
undergoing primary percutaneous coronary intervention in
acute myocardial infarction (from the CADILLAC trial). Am
J Cardiol 2007;99:1055-61.
25) Vidwan P, Lee S, Rossi JS, Stouffer GA. Relation of
platelet count to bleeding and vascular complications in
patients undergoing coronary angiography. Am J Cardiol
2010;105:1219-22.
26) Ommen SR, Hammill SC, Gibbons RJ. The relative
lymphocyte count predicts death in patients receiving
implantable cardioverter defibrillators. Pacing Clin
Electrophysiol 2002;25:1424-8.
27) Acanfora D, Gheorghiade M, Trojano L, Furgi G, Pasini
E, Picone C, et al. Relative lymphocyte count: a prognostic
indicator of mortality in elderly patients with congestive
heart failure. Am Heart J 2001;142:167-73.
28) Zouridakis EG, Garcia-Moll X, Kaski JC. Usefulness of the
blood lymphocyte count in predicting recurrent instability
and death in patients with unstable angina pectoris. Am J
Cardiol 2000;86:449-51.
29) Bhutta H, Agha R, Wong J, Tang TY, Wilson YG, Walsh SR.
Neutrophil-lymphocyte ratio predicts medium-term survival
following elective major vascular surgery: a cross-sectional
study. Vasc Endovascular Surg 2011;45:227-31.
30) Spark JI, Sarveswaran J, Blest N, Charalabidis P, Asthana
S. An elevated neutrophil-lymphocyte ratio independently
predicts mortality in chronic critical limb ischemia. J Vasc
Surg 2010;52:632-6.
31) Ott I, Neumann FJ, Gawaz M, Schmitt M, Schömig A.
Increased neutrophil-platelet adhesion in patients with
unstable angina. Circulation 1996;94:1239-46.
32) Gennari R, Dominioni L, Imperatori A, Bianchi V,
Maroni P, Dionigi R. Alterations in lymphocyte subsets
as prognosticators of postoperative infections. Eur J Surg
1995;161:493-9.
33) Dionigi R, Dominioni L, Benevento A, Giudice G, Cuffari S,
Bordone N, et al. Effects of surgical trauma of laparoscopic
vs. open cholecystectomy. Hepatogastroenterology
1994;41:471-6.
34) Pechan I, Holoman M, Zahorec R, Rendekova V, Kalnovicova
T, Hola J, et al. Parameters of energy metabolism in patients
after vascular reconstructive surgical procedures. Bratisl Lek
Listy 1999;100:439-44. [Abstract]
35) Chung J, Corriere MA, Veeraswamy RK, Kasirajan K,
Milner R, Dodson TF, et al. Risk factors for late mortality
after endovascular repair of the thoracic aorta. J Vasc Surg
2010;52:549-54.
36) Haumer M, Amighi J, Exner M, Mlekusch W, Sabeti S,
Schlager O, et al. Association of neutrophils and future
cardiovascular events in patients with peripheral artery
disease. J Vasc Surg 2005;41:610-7.
37) Mueller C, Neumann FJ, Hochholzer W, Trenk D, Zeller
T, Perruchoud AP, et al. The impact of platelet count
on mortality in unstable angina/non-ST-segment elevation
myocardial infarction. Am Heart J 2006;151:1214.e1-7.
38) Azab B, Shah N, Akerman M, McGinn JT Jr. Value of
platelet/lymphocyte ratio as a predictor of all-cause mortality
after non-ST-elevation myocardial infarction. J Thromb
Thrombolysis 2012;34:326-34.